«Microenvironment of hematopoietic stem cells can be a target
for myeloproliferative disorders.»
Not exact matches
The team has shown that the microenvironment that controls hematopoietic stem cells can be targeted
for the treatment of a set of
disorders called
myeloproliferative neoplasias, the most prominent of which are chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), and atypical chronic myelogenous leukemia (CML).
Relevance to practice: Identification of the Val617Phe JAK2 mutation lays the foundation
for new approaches to the diagnosis, classification, and treatment of
myeloproliferative disorders.
4/7/2008 From Bench to Bedside in One Year: Stem Cell Research Leads to Potential New Therapy
for Rare Blood
Disorder A unique partnership between industry and academia has led to human clinical trials of a new drug
for a rare class of blood diseases called
myeloproliferative disorders (MPD), which are all driven by the same genetic mutation and can evolve into leuk... More...
The Johns Hopkins Center
for the Chronic
Myeloproliferative Disorders coordinates the care of patients with PV and other related
disorders and conducts research in these areas.